 WALTHAM, Mass., Nov. 02, 2022 GLOBE NEWSWIRE -- Dyne Therapeutics, Inc. Nasdaq: DYN, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November: 